These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 10954036

  • 1. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY.
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [Abstract] [Full Text] [Related]

  • 2. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ, Beil ME, Bruseo CW, Fink CA, Hoyer D, Savage P, Jeng AY.
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [Abstract] [Full Text] [Related]

  • 3. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Jeng AY, Savage P, Beil ME, Bruseo CW, Hoyer D, Fink CA, Trapani AJ.
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
    Trapani AJ, De Lombaert S, Kuzmich S, Jeng AY.
    J Cardiovasc Pharmacol; 1995 Aug; 26 Suppl 3():S69-71. PubMed ID: 8587471
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
    De Lombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL.
    Biochem Biophys Res Commun; 1994 Oct 14; 204(1):407-12. PubMed ID: 7945387
    [Abstract] [Full Text] [Related]

  • 6. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY.
    J Cardiovasc Pharmacol; 2004 Nov 14; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [Abstract] [Full Text] [Related]

  • 7. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, Fitt J, Hoyer D, Simonsbergen D, Moliterni J, Marcopoulos N, Savage P, Chou M, Trapani AJ, Jeng AY.
    J Med Chem; 2000 Feb 10; 43(3):488-504. PubMed ID: 10669576
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME.
    J Hypertens; 2002 Apr 10; 20(4):707-14. PubMed ID: 11910307
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY.
    J Cardiovasc Pharmacol; 2000 Nov 10; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [Abstract] [Full Text] [Related]

  • 10. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B.
    Am J Hypertens; 2005 Dec 10; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [Abstract] [Full Text] [Related]

  • 11. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M.
    Hypertension; 2005 Jun 10; 45(6):1145-52. PubMed ID: 15897363
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
    Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ.
    J Cardiovasc Pharmacol; 2000 Nov 10; 36(5 Suppl 1):S36-9. PubMed ID: 11078330
    [Abstract] [Full Text] [Related]

  • 13. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.
    Shetty SS, Savage P, DelGrande D, De Lombaert S, Jeng AY.
    J Cardiovasc Pharmacol; 1998 Nov 10; 31 Suppl 1():S68-70. PubMed ID: 9595403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
    Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP.
    Life Sci; 2012 Oct 15; 91(13-14):743-8. PubMed ID: 22480515
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
    Yap EY, Battistini B, McKay KO.
    Br J Pharmacol; 2000 Jan 15; 129(1):170-6. PubMed ID: 10694217
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY.
    J Cardiovasc Pharmacol; 1998 Jan 15; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.